New mRNA flu shot passes first safety test in small human trial
NCT ID NCT05755620
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 28 times
Summary
This early-stage study tested a single dose of an experimental mRNA flu vaccine in 50 healthy adults aged 18 to 49. The main goal was to check safety at three different dose levels. A small group also received a standard flu shot for comparison. The study is complete and helps pave the way for future flu vaccines.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27704, United States
Conditions
Explore the condition pages connected to this study.